Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

New Radiomedicine Technology

Request full access

New Radiomedicine Technology is a research, production and sales company

Chengdu, ChinaFounded 2016Biotech & Life Sciences

About New Radiomedicine Technology

Chengdu New Radiomedicine Technology Co., Ltd. (NRT) is a biopharmaceutical company established in 2016, concentrating on the development and commercialization of radiopharmaceuticals. It was founded by Jiming Cai, Jihui Qian, and Maoliang Li, who are described as veterans in the nuclear medicine technology field. The company is headquartered in Chengdu, China, a significant hub for the nuclear industry, and has expanded its presence with four domestic subsidiaries and international offices in San Diego, USA, and Melbourne, Australia.

NRT's business model encompasses the entire value chain, from the production of medical isotopes to the innovation, research, and development of radiopharmaceutical drugs. The company serves the oncology market by providing hospitals and medical institutions with drugs for both the diagnosis and treatment of various cancers. Its revenue generation is supported by venture capital funding, with a Series C funding round in March 2024 raising over 300 million yuan ($41.8M USD) to advance its research and production capabilities. NRT also provides Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) services.

The company's core offering is a portfolio of radiopharmaceuticals, which are drugs containing radioactive elements used for medical imaging and therapy. A key area of focus is Radioligand Therapy (RLT), a targeted approach that delivers cytotoxic radiation directly to cancer cells by binding to specific biomarkers, thereby minimizing damage to healthy tissue. NRT's product pipeline includes TareSphere™, Yttrium-90 carbon microspheres for treating cancers with minimally invasive procedures, which are currently in late-stage clinical trials. It has also developed proprietary generator systems, the Galliator™ (Gallium-68) and Techneator™ (Technetium-99), and produces key medical isotopes like Lutetium-177. To support its production, NRT is installing a high-capacity Cyclone® IKON cyclotron, expected to be operational by 2025, which will produce a range of isotopes crucial for theranostics.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
41
Dealroom signal
23.0/100
Industry
Health, Marketing
Sub-industry
Pharmaceutical, BioTechnology, CRM & Sales
Sector
Oncology, Radiology, Radioisotope Therapeutics, Hard Tech, biomanufacturing, DT and LS, science-based
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES EOther financing Apr 2026 $138M $550M Cornerstone Capital · Yuekai Securities · Nanjing Gaoke · Sichuan Venture Capital ↗
SERIES DOther financing Oct 2025 $110M $440M Zhongqi Private Equity Fund Management (Hainan) · CNNC Industry Fund · Guangdong Hengjian Investment · PICC Capital Investment Management ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

New Radiomedicine Technology website traffic

Latest recorded traffic for New Radiomedicine Technology is 1.6K monthly website visits, up 5233.3% over the last three months.

Latest monthly visits1.6K 3-month web change+5233.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

New Radiomedicine Technology in the Chengdu ecosystem

Live from Dealroom

The New Radiomedicine Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

22 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • BTG

Series B and later21 investors entered at this stage

  • Chengdu Science and Technology Venture Capital
  • Star Capital
  • Xinjun Capital
  • Sichuan Innovation Development Investment Management
  • Chengdu Biocity Fund
  • Huaxing Kangping
  • PICC Capital Investment Management
  • Shenzhen Capital Group
  • Zhongqi Private Equity Fund Management (Hainan)
  • CNNC Industry Fund
  • Guangdong Hengjian Investment
  • AstraZeneca Pharmaceutical
  • Chasing Financial
  • Shanghai Science and Technology Innovation Center
  • Cornerstone Capital
  • Yuekai Securities
  • Nanjing Gaoke
  • Sichuan Venture Capital
  • Shanghai Guoxin Venture Capital
  • Pudong Venture Capital
  • Yifeng Capital
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about New Radiomedicine Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See New Radiomedicine Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.